# ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer

Source: https://onco.cc/trials/nct07188025/  
OnCo record `nct07188025` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in colorectal cancer, run by Erasmus Medical Center, now recruiting.

## Summary

ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer is a phase 3, randomised interventional study registered as NCT07188025 by Erasmus Medical Center, with a registry enrolment figure of 103 participants, started 2025-10-14 and due to reach its primary completion in 2030-10. Interventions recorded: Adjuvant chemotherapy. Conditions listed: Rectal Cancer. Primary outcome: Disease-free survival, intention-to-treat. Colorectal eligibility wording from the registry: "* Histological confirmed rectal cancer; either treated with neoadjuvant (chemo)radiotherapy, and/or clinical/pathological T3/T4 and/or N+ in case no neoadjuvant therapy was administered". Sites: Netherlands. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: REACT
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07188025
- Phase: 3
- Setting: Adjuvant Chemotherapy for Prevention of Recurrence in Patients With Detectable ctDNA After Surgery in High-Risk Rectal Cancer
- Sponsor: Erasmus Medical Center
- Enrolled: 103

## Sources

- ClinicalTrials.gov NCT07188025: https://clinicaltrials.gov/study/NCT07188025

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07188025.json